Evaluation of the In-Vitro Effects of Albendazole, Mebendazole, and Praziquantel Nanocapsules against Protoscolices of Hydatid Cyst
Pathogens · 2024
DOI: 10.3390/pathogens13090790 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pathogens, 2024. Verfasst von Nooshinmehr Soleymani und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathobiology, Faculty of Veterinary Medicine, Ferdowsi University of Mashhad, Mashhad P.O. Box 9177948974, Iran. Hauptthemen laut MEDLINE: Albendazole, Mebendazole, Nanocapsules, Praziquantel. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 113 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ferdowsi University of Mashhad.
Abstract (Originalsprache)
Cystic echinococcosis still remains a serious health and economic problem worldwide. The etiologic agent is Echinococcus granulosus sensu lato, giving origin to a fluid-filled cystic lesion. Therapy faces several challenges. Nanodrugs have shown promise as chemotherapeutics against hydatid cysts. The present study evaluated a highly safe lipid nano-polymeric capsule for its superior efficacy and ability to overcome drug resistance. Nanocapsule drugs were formulated into six groups: Albendazole, mebendazole, praziquantel, albendazole + mebendazole, albendazole + praziquantel, and praziquantel + mebendazole. The protoscolicidal effects of these six groups were assessed at 10, 60, and 120 min in three concentrations (1, 0.5, and 0.25 mg/mL). Drug formulations were evaluated via zeta potential, droplet size, solubility, particle size analyzer (PSA), and scanning electron microscopy. According to the PSA results, the mean size of the albendazole nanocapsules was 193.01 nm, mebendazole was 170.40 nm, and praziquantel was 180.44 nm. Albendazole + mebendazole showed the greatest protoscolicidal activity at a concentration of 1 mg/mL after 120 min. In contrast, each drug’s 0.25 mg/mL single-dose times showed the least protoscolicidal activity after 120 min. With the right application of nanotechnology, it is possible to produce safe and effective drugs, such as the polymeric combination of albendazole and mebendazole, which has promising implications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathobiology, Faculty of Veterinary Medicine, Ferdowsi University of Mashhad, Mashhad P.O. Box 9177948974, Iran.
- WOAH and NRL for Echinococcosis, Animal Health, Istituto Zooprofilattico Sperimentale della Sardegna, 07100 Sassari, Italy.
- Department of Physics, University of Zabol, Zabol P.O. Box 538-98615, Iran.
ORCID-Profile: Soheil Sadr, Cinzia Santucciu, Abbas Rahdar, Hassan Borji
Förderung
- Ferdowsi University of Mashhad
Zitieren
APA
Soleymani, N., Sadr, S., Santucciu, C., Rahdar, A., Masala, G., & Borji, H. (2024). Evaluation of the In-Vitro Effects of Albendazole, Mebendazole, and Praziquantel Nanocapsules against Protoscolices of Hydatid Cyst. Pathogens. https://doi.org/10.3390/pathogens13090790
Vancouver
Soleymani N, Sadr S, Santucciu C, Rahdar A, Masala G, Borji H. Evaluation of the In-Vitro Effects of Albendazole, Mebendazole, and Praziquantel Nanocapsules against Protoscolices of Hydatid Cyst. Pathogens. 2024. doi:10.3390/pathogens13090790
BibTeX
@article{Soleymani2024,
author = {Soleymani, Nooshinmehr and Sadr, Soheil and Santucciu, Cinzia and Rahdar, Abbas and Masala, Giovanna and Borji, Hassan},
title = {Evaluation of the In-Vitro Effects of Albendazole, Mebendazole, and Praziquantel Nanocapsules against Protoscolices of Hydatid Cyst},
journal = {Pathogens},
year = {2024},
doi = {10.3390/pathogens13090790}
}
EUVIMED